title: Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Pollyea
authors.forename: Aparna
authors.initials: A
authors.lastname: Raval
authors.forename: Brenda
authors.initials: B
authors.lastname: Kusler
authors.forename: Jason R
authors.initials: JR
authors.lastname: Gotlib
authors.forename: Ash A
authors.initials: AA
authors.lastname: Alizadeh
authors.forename: Beverly S
authors.initials: BS
authors.lastname: Mitchell
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000595:Amino Acid Sequence; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors*; D004268:DNA-Binding Proteins / Q000235:genetics*; D049308:Dioxygenases; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors; D011518:Proto-Oncogene Proteins; D012333:RNA, Messenger; D049308:Dioxygenases; C541081:TET2 protein, human; D004248:DNA (Cytosine-5-)-Methyltransferases